https://m2.mtmt.hu/ hun 2026-09-22 14:59 JournalArticle 34884013 VALIDATED true 0 false 2026-05-23T21:03:17.640+0000 2026-02-21T17:13:06.663+0000 2024-05-28T11:59:19.942+0000 true 10028537 Baczkó Gabriella /api/admin/10028537 Admin Baczkó Gabriella (SZTE SZAOK admin5 Szemészeti Klinika) true 10028537 2026-02-21T17:13:06.885+0000 2026-02-21T17:13:06.885+0000 2025-03-16T19:56:29.298+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Zhao, Z. true true /api/journal/10044691 REVIEWED EBIOMEDICINE 2352-3964 2352-3964 true false 10044691 false 10044691 true 2352-3964 2352-3964 Journal FOREIGN 103 105108 105108 18 2024 The clinical significance of optimal pharmacotherapy for inherited arrhythmias such as short QT syndrome (SQTS) and long QT syndrome (LQTS) has been increasingly recognised. The advancement of gene technology has opened up new possibilities for identifying genetic variations and investigating the pathophysiological roles and mechanisms of genetic arrhythmias. Numerous variants in various genes have been proven to be causative in genetic arrhythmias. Studies have demonstrated that the effectiveness of certain drugs is specific to the patient or genotype, indicating the important role of gene-variants in drug response. This review aims to summarize the reported data on the impact of different gene-variants on drug response in SQTS and LQTS, as well as discuss the potential mechanisms by which gene-variants alter drug response. These findings may provide valuable information for future studies on the influence of gene variants on drug efficacy and the development of genotype-guided or precision treatment for these diseases. © 2024 The Author(s) 2024 true true true false false NONE 2026-05-23 false 5 0 5 3 0 5 5 5 3 5 5 3 3 3 2 0 5 3 5 3 0 2 2 Folyóiratcikk Journal Article 24 5 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 1 0 1 0 2025 0 1 1 1 1 2026 0 3 2 3 2 D1 false false false false 2024-08-26T11:59:58.994+0000 HCEMM- SE Kardiovaszkuláris Komorbiditások Kuta... (SE / AOK / I / FFI) 1 8 1 12 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 116818299 /api/authorship/116818299 Zhao, Z. 1 0.083333336 true false false Zhao Z. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818300 /api/authorship/116818300 Zang, X.* 2 0.083 true false false Zang X. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818301 /api/authorship/116818301 Niu, K. 3 0.083333336 false false false Niu K. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818302 /api/authorship/116818302 Song, W. 4 0.083333336 false false false Song W. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818303 /api/authorship/116818303 Wang, X. 5 0.083333336 false false false Wang X. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818304 /api/authorship/116818304 Mügge, A. 6 0.083333336 false false false Mügge A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818305 /api/authorship/116818305 Aweimer, A. 7 0.083333336 false false false Aweimer A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818306 /api/authorship/116818306 Hamdani, N. [Hamdani, Nazha (Medicine), szerző] HCEMM- SE Kardiovaszkuláris Komorbiditások Kuta... (SE / AOK / I / FFI) 8 0.083 false false false Author 10086357 /api/author/10086357 Hamdani Nazha (Medicine) Hamdani Nazha true true Hamdani N. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818307 /api/authorship/116818307 Zhou, X. ✉ 9 0.083333336 false false true Zhou X. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818308 /api/authorship/116818308 Zhao, Y. ✉ 10 0.083333336 false false true Zhao Y. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818309 /api/authorship/116818309 Akin, I.** 11 0.083 false true false Akin I. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116818310 /api/authorship/116818310 El-Battrawy, I. 12 0.083 false true false El-Battrawy I. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 26261243 /api/publicationidentifier/26261243 DOI: 10.1016/j.ebiom.2024.105108 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.ebiom.2024.105108 https://doi.org/10.1016/j.ebiom.2024.105108 false true PublicationIdentifier 26984117 /api/publicationidentifier/26984117 WoS: 001295888500001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001295888500001 https://www.webofscience.com/wos/woscc/full-record/001295888500001 false true PublicationIdentifier 26261242 /api/publicationidentifier/26261242 Scopus: 85190829849 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85190829849 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85190829849 false true PublicationIdentifier 26989100 /api/publicationidentifier/26989100 PubMed: 38653189 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38653189 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38653189&dopt=Abstract false true Keyword 65 /api/keyword/65 Humans true 65 true Keyword 651 /api/keyword/651 GENETICS true 651 true Keyword 3118 /api/keyword/3118 review true 3118 true Keyword 3122 /api/keyword/3122 human true 3122 true Keyword 4196 /api/keyword/4196 Treatment Outcome true 4196 true Keyword 4196 /api/keyword/4196 Treatment Outcome true 4196 true Keyword 4225 /api/keyword/4225 Genotype true 4225 true Keyword 4225 /api/keyword/4225 Genotype true 4225 true Keyword 4506 /api/keyword/4506 drug response true 4506 true Keyword 4553 /api/keyword/4553 Genetic Predisposition to Disease true 4553 true Keyword 5079 /api/keyword/5079 nonhuman true 5079 true Keyword 6597 /api/keyword/6597 verapamil true 6597 true Keyword 11029 /api/keyword/11029 Genetic Variation true 11029 true Keyword 11029 /api/keyword/11029 Genetic Variation true 11029 true Keyword 14018 /api/keyword/14018 heart failure true 14018 true Keyword 14019 /api/keyword/14019 heart arrhythmia true 14019 true Keyword 14019 /api/keyword/14019 heart arrhythmia true 14019 true Keyword 18414 /api/keyword/18414 carvedilol true 18414 true Keyword 18640 /api/keyword/18640 LONG QT SYNDROME true 18640 true Keyword 18640 /api/keyword/18640 LONG QT SYNDROME true 18640 true Keyword 20139 /api/keyword/20139 genetic predisposition true 20139 true Keyword 1009098 /api/keyword/1009098 channelopathy true 1009098 true Keyword 1020066 /api/keyword/1020066 Drug therapy true 1020066 true Keyword 1021959 /api/keyword/1021959 loss of function mutation true 1021959 true Keyword 1035042 /api/keyword/1035042 LONG-QT SYNDROME true 1035042 true Keyword 1041796 /api/keyword/1041796 pharmacodynamics true 1041796 true Keyword 1043397 /api/keyword/1043397 bupivacaine true 1043397 true Keyword 1048231 /api/keyword/1048231 voltage gated potassium channel true 1048231 true Keyword 1062428 /api/keyword/1062428 propafenone true 1062428 true Keyword 1076070 /api/keyword/1076070 Anti-Arrhythmia Agents true 1076070 true Keyword 1076071 /api/keyword/1076071 antiarrhythmic agent true 1076071 true Keyword 1080354 /api/keyword/1080354 sotalol true 1080354 true Keyword 1080357 /api/keyword/1080357 mexiletine true 1080357 true Keyword 1087392 /api/keyword/1087392 disopyramide true 1087392 true Keyword 1092060 /api/keyword/1092060 Ivabradine true 1092060 true Keyword 1105433 /api/keyword/1105433 Arrhythmias, Cardiac true 1105433 true Keyword 1115115 /api/keyword/1115115 ANTI-ARRHYTHMIC DRUGS true 1115115 true Keyword 1131293 /api/keyword/1131293 gain of function mutation true 1131293 true Keyword 1131371 /api/keyword/1131371 induced pluripotent stem cell true 1131371 true Keyword 1256371 /api/keyword/1256371 sodium channel Nav1.5 true 1256371 true Keyword 1510584 /api/keyword/1510584 pharmacogenetic variant true true Keyword 1510587 /api/keyword/1510587 Pharmacogenomic Variants true true Keyword 1511221 /api/keyword/1511221 ranolazine true true Keyword 1516369 /api/keyword/1516369 short QT syndrome true true Keyword 1517017 /api/keyword/1517017 ibutilide true true Keyword 1532777 /api/keyword/1532777 SHORT-QT SYNDROME true true Keyword 1744044 /api/keyword/1744044 ajmaline true true Keyword 3388053 /api/keyword/3388053 Gene variant-guided-therapy true true Keyword 3388054 /api/keyword/3388054 Gene-variants true true SjrRating 11443677 /api/sjrrating/11443677 sjr:D1 (2024) Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) EBIOMEDICINE 2352-3964 2352-3964 19 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1301 /api/classificationexternal/1301 Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) true 1301 true D1 DIRECT true true Reference 53613491 /api/reference/53613491 1. Krahn, A.D., Laksman, Z., Sy, R.W., Congenital long QT syndrome (2022) JACC Clin Electrophysiol, 8 (5), pp. 687-706 1 false true Reference 53613492 /api/reference/53613492 2. Nikoo, M.H., Heiran, A., Mashayekh, F., Rezaianzadeh, A., Shiravani, A., Azadian, F., A descriptive report on short QT interval in Kherameh branch of the Persian cohort study (2022) Sci Rep, 12 (1), p. 2898 2 false true Reference 53613493 /api/reference/53613493 3. Orvos, P., Kohajda, Z., Szlovák, J., Evaluation of possible proarrhythmic potency: comparison of the effect of dofetilide, cisapride, sotalol, terfenadine, and verapamil on hERG and native IKr currents and on cardiac action potential (2019) Toxicol Sci, 168 (2), pp. 365-380 3 false true Reference 53613494 /api/reference/53613494 4. McPate, M.J., Duncan, R.S., Hancox, J.C., Witchel, H.J., Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs (2008) Br J Pharmacol, 155 (6), pp. 957-966 4 false true Reference 53613495 /api/reference/53613495 5. Gaita, F., Giustetto, C., Bianchi, F., Short QT syndrome: pharmacological treatment (2004) J Am Coll Cardiol, 43 (8), pp. 1494-1499 5 false true Reference 53613496 /api/reference/53613496 6. Zhao, Z., Li, X., El-Battrawy, I., Drug testing in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 (2019) Clin Pharmacol Ther, 106 (3), pp. 642-651 6 false true Reference 53613497 /api/reference/53613497 7. Huang, M., Liao, Z., Li, X., Effects of antiarrhythmic drugs on hERG gating in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 (2021) Front Pharmacol, 12 7 false true Reference 53613498 /api/reference/53613498 8. Dewi, I.P., Dharmadjati, B.B., Short QT syndrome: the current evidences of diagnosis and management (2020) J Arrhythm, 36 (6), pp. 962-966 8 false true Reference 53613499 /api/reference/53613499 9. Brugada, J., Gussak, I., Brugada, P., Short QT syndrome: a predictable story (2014) Cardiology, 128 (3), pp. 231-233 9 false true Reference 53613500 /api/reference/53613500 10. Zeppenfeld, K., Tfelt-Hansen, J., de Riva, M., ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (2022) Eur Heart J, 2022 10 false true Reference 53613501 /api/reference/53613501 11. Fan, X., Yang, G., Kowitz, J., Preclinical short QT syndrome models: studying the phenotype and drug-screening (2022) Europace, 24 (3), pp. 481-493 11 false true Reference 53613502 /api/reference/53613502 12. Thorsen, K., Dam, V.S., Kjaer-Sorensen, K., Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome (2017) Nat Commun, 8 (1), p. 1696 12 false true Reference 53613503 /api/reference/53613503 13. Christiansen, M.K., Kjær-Sørensen, K., Clavsen, N.C., Genetic analysis identifies the SLC4A3 anion exchanger as a major gene for short QT syndrome (2023) Heart Rhythm, 20 (8), pp. 1136-1143 13 false true Reference 53613504 /api/reference/53613504 14. Walsh, R., Adler, A., Amin, A.S., Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death (2022) Eur Heart J, 43 (15), pp. 1500-1510 14 false true Reference 53613505 /api/reference/53613505 15. Butler, A., Helliwell, M.V., Zhang, Y., Hancox, J.C., Dempsey, C.E., An update on the structure of hERG (2019) Front Pharmacol, 10, p. 1572 15 false true Reference 53613506 /api/reference/53613506 16. Sun, Y., Quan, X.Q., Fromme, S., A novel mutation in the KCNH2 gene associated with short QT syndrome (2011) J Mol Cell Cardiol, 50 (3), pp. 433-441 16 false true Reference 53613507 /api/reference/53613507 17. Itoh, H., Sakaguchi, T., Ashihara, T., A novel KCNH2 mutation as a modifier for short QT interval (2009) Int J Cardiol, 137 (1), pp. 83-85 17 false true Reference 53613508 /api/reference/53613508 18. Redpath, C.J., Green, M.S., Birnie, D.H., Gollob, M.H., Rapid genetic testing facilitating the diagnosis of short QT syndrome (2009) Can J Cardiol, 25 (4), pp. e133-e135 18 false true Reference 53613509 /api/reference/53613509 19. Butler, A., Zhang, Y., Stuart, A.G., Dempsey, C.E., Hancox, J.C., Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome (2019) Heliyon, 5 (4) 19 false true Reference 53613510 /api/reference/53613510 20. Akdis, D., Saguner, A.M., Medeiros-Domingo, A., Multiple clinical profiles of families with the short QT syndrome (2018) Europace, 20 (Fi1), pp. f113-f121 20 false true Reference 53613511 /api/reference/53613511 21. Hu, D., Li, Y., Zhang, J., The phenotypic spectrum of a mutation hotspot responsible for the short QT syndrome (2017) JACC Clin Electrophysiol, 3 (7), pp. 727-743 21 false true Reference 53613512 /api/reference/53613512 22. Bellocq, C., van Ginneken, A.C., Bezzina, C.R., Mutation in the KCNQ1 gene leading to the short QT-interval syndrome (2004) Circulation, 109 (20), pp. 2394-2397 22 false true Reference 53613513 /api/reference/53613513 23. Wu, Z.J., Huang, Y., Fu, Y.C., Characterization of a Chinese KCNQ1 mutation (R259H) that shortens repolarization and causes short QT syndrome 2 (2015) J Geriatr Cardiol, 12 (4), pp. 394-401 23 false true Reference 53613514 /api/reference/53613514 24. Moreno, C., Oliveras, A., de la Cruz, A., A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome (2015) Cardiovasc Res, 107 (4), pp. 613-623 24 false true Reference 53613515 /api/reference/53613515 25. Hancox, J.C., Du, C.Y., Butler, A., Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome (2023) Phil Trans Roy Soc Lond B Biol Sci, 378 (1879) 25 false true Reference 53613516 /api/reference/53613516 26. Du, C., Rasmusson, R.L., Bett, G.C., Franks, B., Zhang, H., Hancox, J.C., Investigation of the effects of the short QT syndrome D172N Kir 2.1 mutation on ventricular action potential profile using dynamic clamp (2021) Front Pharmacol, 12 26 false true Reference 53613517 /api/reference/53613517 27. Yang, D., Wan, X., Dennis, A.T., MicroRNA biophysically modulates cardiac action potential by direct binding to Ion channel (2021) Circulation, 143 (16), pp. 1597-1613 27 false true Reference 53613518 /api/reference/53613518 28. Jeong, D.U., Lee, J., Lim, K.M., Computational study to identify the effects of the KCNJ2 E299V mutation in cardiac pumping capacity (2020) Comput Math Methods Med, 2020 28 false true Reference 53613519 /api/reference/53613519 29. Antzelevitch, C., Pollevick, G.D., Cordeiro, J.M., Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death (2007) Circulation, 115 (4), pp. 442-449 29 false true Reference 53613520 /api/reference/53613520 30. Chen, Y., Barajas-Martinez, H., Zhu, D., Erratum to: novel trigenic CACNA1C/DES/MYPN mutations in a family of hypertrophic cardiomyopathy with early repolarization and short QT syndrome (2017) J Transl Med, 15 (1), p. 101 30 false true Reference 53613521 /api/reference/53613521 31. Templin, C., Ghadri, J.R., Rougier, J.S., Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6) (2011) Eur Heart J, 32 (9), pp. 1077-1088 31 false true Reference 53613522 /api/reference/53613522 32. Hong, K., Hu, J., Yu, J., Brugada, R., Concomitant Brugada-like and short QT electrocardiogram linked to SCN5A mutation (2012) Eur J Hum Genet, 20 (11), pp. 1189-1192 32 false true Reference 53613523 /api/reference/53613523 33. Sottas, V., Rougier, J.S., Jousset, F., Characterization of 2 genetic variants of Na(v) 1.5-arginine 689 found in patients with cardiac arrhythmias (2013) J Cardiovasc Electrophysiol, 24 (9), pp. 1037-1046 33 false true Reference 53613524 /api/reference/53613524 34. Brugada, R., Hong, K., Dumaine, R., Sudden death associated with short-QT syndrome linked to mutations in HERG (2004) Circulation, 109 (1), pp. 30-35 34 false true Reference 53613525 /api/reference/53613525 35. McPate, M.J., Duncan, R.S., Witchel, H.J., Hancox, J.C., Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome (2006) J Mol Cell Cardiol, 41 (3), pp. 563-566 35 false true Reference 53613526 /api/reference/53613526 36. Chinushi, M., Sato, A., Izumi, D., Furushima, H., Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short-QT syndrome (2012) J Cardiovasc Electrophysiol, 23 (8), pp. 877-880 36 false true Reference 53613527 /api/reference/53613527 37. Giustetto, C., Scrocco, C., Giachino, D., Rapezzi, C., Mognetti, B., Gaita, F., The lack of effect of sotalol in short QT syndrome patients carrying the T618I mutation in the KCNH2 gene (2015) HeartRhythm Case Rep, 1 (5), pp. 373-378 37 false true Reference 53613528 /api/reference/53613528 38. Wolpert, C., Schimpf, R., Giustetto, C., Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG (2005) J Cardiovasc Electrophysiol, 16 (1), pp. 54-58 38 false true Reference 53613529 /api/reference/53613529 39. Bodi, I., Franke, G., Pantulu, N.D., Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels (2013) J Cardiovasc Electrophysiol, 24 (10), pp. 1163-1171 39 false true Reference 53613530 /api/reference/53613530 40. Frommeyer, G., Ellermann, C., Dechering, D.G., Ranolazine and vernakalant prevent ventricular arrhythmias in an experimental whole-heart model of short QT syndrome (2016) J Cardiovasc Electrophysiol, 27 (10), pp. 1214-1219 40 false true Reference 53613531 /api/reference/53613531 41. El-Battrawy, I., Lan, H., Cyganek, L., Modeling short QT syndrome using human-induced pluripotent stem cell-derived cardiomyocytes (2018) J Am Heart Assoc, 7 (7) 41 false true Reference 53613532 /api/reference/53613532 42. Shinnawi, R., Shaheen, N., Huber, I., Modeling reentry in the short QT syndrome with human-induced pluripotent stem cell-derived cardiac cell sheets (2019) J Am Coll Cardiol, 73 (18), pp. 2310-2324 42 false true Reference 53613533 /api/reference/53613533 43. Shiti, A., Arbil, G., Shaheen, N., Huber, I., Setter, N., Gepstein, L., Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome (2023) J Mol Cell Cardiol, 183, p. 4 43 false true Reference 53613534 /api/reference/53613534 44. Lan, H., Xu, Q., El-Battrawy, I., Ionic mechanisms of disopyramide prolonging action potential duration in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 (2020) Front Pharmacol, 11 44 false true Reference 53613535 /api/reference/53613535 45. Xu, Q., Huang, X., Meng, Z., Antiarrhythmic effects of vernakalant in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 (2022) J Cardiovasc Dev Dis, 9 (4) 45 false true Reference 53613536 /api/reference/53613536 46. Jæger, K.H., Wall, S., Tveito, A., Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes (2021) PLoS Comput Biol, 17 (2) 46 false true Reference 53613537 /api/reference/53613537 47. Whittaker, D.G., Colman, M.A., Ni, H., Hancox, J.C., Zhang, H., Human atrial arrhythmogenesis and sinus bradycardia in KCNQ1-linked short QT syndrome: insights from computational modelling (2018) Front Physiol, 9, p. 1402 47 false true Reference 53613538 /api/reference/53613538 48. Cunjin, L., Kuanquan, W., Henggui, Z., Modeling the effects of amiodarone on short QT syndrome variant 2 in the human ventricles (2017) Annu Int Conf IEEE Eng Med Biol Soc, 2017, pp. 4273-4276 48 false true Reference 53613539 /api/reference/53613539 49. An, M.Y., Sun, K., Li, Y., Therapeutic effects of a taurine-magnesium coordination compound on experimental models of type 2 short QT syndrome (2018) Acta Pharmacol Sin, 39 (3), pp. 382-392 49 false true Reference 53613540 /api/reference/53613540 50. Mazzanti, A., Maragna, R., Vacanti, G., Hydroquinidine prevents life-threatening arrhythmic events in patients with short QT syndrome (2017) J Am Coll Cardiol, 70 (24), pp. 3010-3015 50 false true Reference 53613541 /api/reference/53613541 51. Noujaim, S.F., Stuckey, J.A., Ponce-Balbuena, D., Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine (2011) Cardiovasc Res, 89 (4), pp. 862-869 51 false true Reference 53613542 /api/reference/53613542 52. El Harchi, A., McPate, M.J., Zhang, Y., Zhang, H., Hancox, J.C., Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome (2009) J Mol Cell Cardiol, 47 (5), pp. 743-747 52 false true Reference 53613543 /api/reference/53613543 53. Zaks-Makhina, E., Li, H., Grishin, A., Salvador-Recatala, V., Levitan, E.S., Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid (2009) J Biol Chem, 284 (23), pp. 15432-15438 53 false true Reference 53613544 /api/reference/53613544 54. Luo, C., Wang, K., Zhang, H., Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study (2017) Biomed Eng Online, 16 (1), p. 69 54 false true Reference 53613545 /api/reference/53613545 55. Luo, C., Wang, K., Zhang, H., Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles (2017) Physiol Meas, 38 (10), pp. 1859-1873 55 false true Reference 53613546 /api/reference/53613546 56. Luo, C., Wang, K., Liu, T., Zhang, H., Computational analysis of the action of chloroquine on short QT syndrome variant 1 and variant 3 in human ventricles (2018) Annu Int Conf IEEE Eng Med Biol Soc, 2018, pp. 5462-5465 56 false true Reference 53613547 /api/reference/53613547 57. Ren, S., Pang, C., Li, J., Styrax blocks inward and outward current of Kir 2.1 channel (2017) Channels, 11 (1), pp. 46-54 57 false true Reference 53613548 /api/reference/53613548 58. El-Battrawy, I., Besler, J., Li, X., Impact of antiarrhythmic drugs on the outcome of short QT syndrome (2019) Front Pharmacol, 10, p. 771 58 false true Reference 53613549 /api/reference/53613549 59. El-Battrawy, I., Lan, H., Cyganek, L., Deciphering the pathogenic role of a variant with uncertain significance for short QT and Brugada syndromes using gene-edited human-induced pluripotent stem cell-derived cardiomyocytes and preclinical drug screening (2021) Clin Transl Med, 11 (12), p. e646 59 false true Reference 53613550 /api/reference/53613550 60. Zhong, R., Schimanski, T., Zhang, F., A preclinical study on brugada syndrome with a CACNB2 variant using human cardiomyocytes from induced pluripotent stem cells (2022) Int J Mol Sci, 23 (15) 60 false true Reference 53613551 /api/reference/53613551 61. El-Battrawy, I., Lang, S., Zhou, X., Akin, I., Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside (2021) Eur Heart J, 42 (13), pp. 1270-1272 61 false true Reference 53613552 /api/reference/53613552 62. Wilde, A.A.M., Amin, A.S., Postema, P.G., Diagnosis, management and therapeutic strategies for congenital long QT syndrome (2022) Heart, 108 (5), pp. 332-338 62 false true Reference 53613553 /api/reference/53613553 63. Al-Khatib, S.M., Stevenson, W.G., Ackerman, M.J., 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society (2018) J Am Coll Cardiol, 72 (14), pp. e91-e220 63 false true Reference 53613554 /api/reference/53613554 64. Adler, A., Novelli, V., Amin, A.S., An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome (2020) Circulation, 141 (6), pp. 418-428 64 false true Reference 53613555 /api/reference/53613555 65. Giudicessi, J.R., Ackerman, M.J., Genotype- and phenotype-guided management of congenital long QT syndrome (2013) Curr Probl Cardiol, 38 (10), pp. 417-455 65 false true Reference 53613556 /api/reference/53613556 66. Kekenes-Huskey, P.M., Burgess, D.E., Sun, B., Mutation-specific differences in Kv7.1 (KCNQ1) and Kv11.1 (KCNH2) channel dysfunction and long QT syndrome phenotypes (2022) Int J Mol Sci, 23 (13) 66 false true Reference 53613557 /api/reference/53613557 67. Sanguinetti, M.C., Seebohm, G., Physiological functions, biophysical properties, and regulation of KCNQ1 (K(V)7.1) potassium channels (2021) Adv Exp Med Biol, 1349, pp. 335-353 67 false true Reference 53613558 /api/reference/53613558 68. Ono, M., Burgess, D.E., Schroder, E.A., Long QT syndrome type 2: emerging strategies for correcting class 2 KCNH2 (hERG) mutations and identifying new patients (2020) Biomolecules, 10 (8) 68 false true Reference 53613559 /api/reference/53613559 69. Akbuğa, K., Karanfil, M., Same family, same mutation, different ECG (2023) Mol Genet Genomic Med, 11 (1) 69 false true Reference 53613560 /api/reference/53613560 70. Marstrand, P., Almatlouh, K., Kanters, J.K., Long QT syndrome type 1 and 2 patients respond differently to arrhythmic triggers: the TriQarr in vivo study (2021) Heart Rhythm, 18 (2), pp. 241-249 70 false true Reference 53613561 /api/reference/53613561 71. Pierre, M., Djemai, M., Poulin, H., Chahine, M., Na(V)1.5 knockout in iPSCs: a novel approach to study Na(V)1.5 variants in a human cardiomyocyte environment (2021) Sci Rep, 11 (1) 71 false true Reference 53613562 /api/reference/53613562 72. Horigome, H., Ishikawa, Y., Takahashi, K., Yoshinaga, M., Sumitomo, N., Analysis of the shape of the T-wave in congenital long-QT syndrome type 3 by geometric morphometrics (2021) Sci Rep, 11 (1) 72 false true Reference 53613563 /api/reference/53613563 73. Chockalingam, P., Crotti, L., Girardengo, G., Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol (2012) J Am Coll Cardiol, 60 (20), pp. 2092-2099 73 false true Reference 53613564 /api/reference/53613564 74. Abu-Zeitone, A., Peterson, D.R., Polonsky, B., McNitt, S., Moss, A.J., Efficacy of different beta-blockers in the treatment of long QT syndrome (2014) J Am Coll Cardiol, 64 (13), pp. 1352-1358 74 false true Reference 53613565 /api/reference/53613565 75. Steinberg, C., Padfield, G.J., Al-Sabeq, B., Experience with bisoprolol in long-QT1 and long-QT2 syndrome (2016) J Intervent Card Electrophysiol, 47 (2), pp. 163-170 75 false true Reference 53613566 /api/reference/53613566 76. Bos, J.M., Crotti, L., Rohatgi, R.K., Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome (2019) Circ Arrhythm Electrophysiol, 12 (5) 76 false true Reference 53613567 /api/reference/53613567 77. Yokoyama, Y., Aiba, T., Ueda, N., Subcutaneous and transvenous implantable cardioverter defibrillator in high-risk long-QT syndrome type 3 associated with Val411Met mutation in SCN5A (2020) J Cardiol Cases, 22 (5), pp. 238-241 77 false true Reference 53613568 /api/reference/53613568 78. Mazzanti, A., Maragna, R., Faragli, A., Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3 (2016) J Am Coll Cardiol, 67 (9), pp. 1053-1058 78 false true Reference 53613569 /api/reference/53613569 79. Moss, A.J., Zareba, W., Schwarz, K.Q., Rosero, S., McNitt, S., Robinson, J.L., Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome (2008) J Cardiovasc Electrophysiol, 19 (12), pp. 1289-1293 79 false true Reference 53613570 /api/reference/53613570 80. Benhorin, J., Taub, R., Goldmit, M., Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? (2000) Circulation, 101 (14), pp. 1698-1706 80 false true Reference 53613571 /api/reference/53613571 81. Jacobs, A., Knight, B.P., McDonald, K.T., Burke, M.C., Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8) (2006) Heart Rhythm, 3 (8), pp. 967-970 81 false true Reference 53613572 /api/reference/53613572 82. Krause, U., Gravenhorst, V., Kriebel, T., Ruschewski, W., Paul, T., A rare association of long QT syndrome and syndactyly: timothy syndrome (LQT 8) (2011) Clin Res Cardiol, 100 (12), pp. 1123-1127 82 false true Reference 53613573 /api/reference/53613573 83. Bentzen, B.H., Bahrke, S., Wu, K., Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits (2011) J Cardiovasc Pharmacol, 57 (2), pp. 223-230 83 false true Reference 53613574 /api/reference/53613574 84. Castiglione, A., Hornyik, T., Wülfers, E.M., Docosahexaenoic acid normalizes QT interval in long QT type 2 transgenic rabbit models in a genotype-specific fashion (2022) Europace, 24 (3), pp. 511-522 84 false true Reference 53613575 /api/reference/53613575 85. Antoons, G., Oros, A., Beekman, J.D., Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model (2010) J Am Coll Cardiol, 55 (8), pp. 801-809 85 false true Reference 53613576 /api/reference/53613576 86. Nagatomo, T., January, C.T., Makielski, J.C., Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide (2000) Mol Pharmacol, 57 (1), pp. 101-107 86 false true Reference 53613577 /api/reference/53613577 87. Gando, I., Campana, C., Tan, R.B., Cecchin, F., Sobie, E.A., Coetzee, W.A., A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant (2020) J Mol Cell Cardiol, 144, pp. 1-11 87 false true Reference 53613578 /api/reference/53613578 88. Itzhaki, I., Maizels, L., Huber, I., Modelling the long QT syndrome with induced pluripotent stem cells (2011) Nature, 471 (7337), pp. 225-229 88 false true Reference 53613579 /api/reference/53613579 89. Matsa, E., Rajamohan, D., Dick, E., Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation (2011) Eur Heart J, 32 (8), pp. 952-962 89 false true Reference 53613580 /api/reference/53613580 90. Malan, D., Zhang, M., Stallmeyer, B., Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction (2016) Basic Res Cardiol, 111 (2), p. 14 90 false true Reference 53613581 /api/reference/53613581 91. Schwoerer, A.P., Zenouzi, R., Ehmke, H., Friederich, P., Bupivacaine destabilizes action potential duration in cellular and computational models of long QT syndrome 1 (2011) Anesth Analg, 113 (6), pp. 1365-1373 91 false true Reference 53613582 /api/reference/53613582 92. Lu, X., Yang, X., Huang, X., RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties (2013) Heart Rhythm, 10 (1), pp. 128-136 92 false true Reference 53613583 /api/reference/53613583 93. Moss, A.J., Windle, J.R., Hall, W.J., Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial (2005) Ann Noninvasive Electrocardiol, 10 (4), pp. 59-66 93 false true Reference 53613584 /api/reference/53613584 94. Shah, D.P., Baez-Escudero, J.L., Weisberg, I.L., Beshai, J.F., Burke, M.C., Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8) (2012) Pacing Clin Electrophysiol, 35 (3), pp. e62-e64 94 false true Reference 53613585 /api/reference/53613585 95. Bezzerides, V.J., Zhang, A., Xiao, L., Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders (2017) Sci Rep, 7 (1), p. 346 95 false true Reference 53613586 /api/reference/53613586 96. Kim, M., Sager, P.T., Tester, D.J., SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation (2023) Heart Rhythm, 20 (4), pp. 589-595 96 false true Reference 53613587 /api/reference/53613587 97. Giannetti, F., Barbieri, M., Shiti, A., Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2 (2023) Europace, 25 (5) 97 false true Reference 53613588 /api/reference/53613588 98. Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin (2021) Circulation, 143 (22), pp. 2188-2204 98 false true Reference 53613589 /api/reference/53613589 99. Özgür, B.V., Dinçsoy, B., Gedikli, E., Erdemb, A., Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats (2021) Kardiol Pol, 79 (1), pp. 53-57 99 false true Reference 53613590 /api/reference/53613590 100. Barış, V., Gedikli, E., Dinçsoy, A.B., Erdem, A., Empagliflozin significantly prevents QTc prolongation due to amitriptyline intoxication (2023) Cardiovasc J Afr, 34, pp. 1-5 100 false true Reference 53613591 /api/reference/53613591 101. Duran, M., Ziyrek, M., Alsancak, Y., Effects of SGLT2 inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization (2020) Acta Cardiol Sin, 36 (6), pp. 626-632 101 false true Reference 53613592 /api/reference/53613592 102. Wang, S., Morales, M.J., Liu, S., Strauss, H.C., Rasmusson, R.L., Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation (1997) FEBS Lett, 417 (1), pp. 43-47 102 false true Reference 53613593 /api/reference/53613593 103. Ficker, E., Jarolimek, W., Kiehn, J., Baumann, A., Brown, A.M., Molecular determinants of dofetilide block of HERG K+ channels (1998) Circ Res, 82 (3), pp. 386-395 103 false true Reference 53613594 /api/reference/53613594 104. Numaguchi, H., Mullins, F.M., Johnson, J.P., Jr., Probing the interaction between inactivation gating and Dd-sotalol block of HERG (2000) Circ Res, 87 (11), pp. 1012-1018 104 false true Reference 53613595 /api/reference/53613595 105. Lees-Miller, J.P., Duan, Y., Teng, G.Q., Duff, H.J., Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites (2000) Mol Pharmacol, 57 (2), pp. 367-374 105 false true Reference 53613596 /api/reference/53613596 106. Heikal, A.A., Hess, S.T., Baird, G.S., Tsien, R.Y., Webb, W.W., Molecular spectroscopy and dynamics of intrinsically fluorescent proteins: coral red (dsRed) and yellow (Citrine) (2000) Proc Natl Acad Sci U S A, 97 (22), pp. 11996-12001 106 false true Reference 53613597 /api/reference/53613597 107. Zhang, S., Zhou, Z., Gong, Q., Makielski, J.C., January, C.T., Mechanism of block and identification of the verapamil binding domain to HERG potassium channels (1999) Circ Res, 84 (9), pp. 989-998 107 false true Reference 53613598 /api/reference/53613598 108. Yang, B.F., Xu, D.H., Xu, C.Q., Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels (2004) Acta Pharmacol Sin, 25 (5), pp. 554-560 108 false true Reference 53613599 /api/reference/53613599 109. Zhu, W., Mazzanti, A., Voelker, T.L., Predicting patient response to the antiarrhythmic mexiletine based on genetic variation (2019) Circ Res, 124 (4), pp. 539-552 109 false true Reference 53613600 /api/reference/53613600 110. Ruan, Y., Liu, N., Bloise, R., Napolitano, C., Priori, S.G., Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients (2007) Circulation, 116 (10), pp. 1137-1144 110 false true Reference 53613601 /api/reference/53613601 111. Viswanathan, P.C., Bezzina, C.R., George, A.L., Jr., Roden, D.M., Wilde, A.A., Balser, J.R., Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes (2001) Circulation, 104 (10), pp. 1200-1205 111 false true Reference 53613602 /api/reference/53613602 112. Hayama, E., Furutani, Y., Kawaguchi, N., Induced pluripotent stem cell-derived cardiomyocytes with SCN5A R1623Q mutation associated with severe long QT syndrome in fetuses and neonates recapitulates pathophysiological phenotypes (2021) Biology, 10 (10) 112 false true Reference 53613603 /api/reference/53613603 113. Li, G., Woltz, R.L., Wang, C.Y., Gating properties of mutant sodium channels and responses to sodium current inhibitors predict mexiletine-sensitive mutations of long QT syndrome 3 (2020) Front Pharmacol, 11, p. 1182 113 false true Reference 53613604 /api/reference/53613604 114. Huang, H., Priori, S.G., Napolitano, C., O'Leary, M.E., Chahine, M., Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav 1.5 channels (2011) Am J Physiol Heart Circ Physiol, 300 (1), pp. H288-H299 114 false true Reference 53613605 /api/reference/53613605 115. Stutzman, M.J., Gao, X., Kim, M., Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies (2023) Heart Rhythm, 20 (5), pp. 709-717 115 false true Reference 53613606 /api/reference/53613606 116. Kim, H.J., Kim, B.G., Park, J.E., Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment (2019) Sci Rep, 9 (1) 116 false true Reference 53613607 /api/reference/53613607 117. Ma, D., Wei, H., Zhao, Y., Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells (2013) Int J Cardiol, 168 (6), pp. 5277-5286 117 false true Reference 53613608 /api/reference/53613608 118. Kanters, J.K., Yuan, L., Hedley, P.L., Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A (2014) Circ J, 78 (5), pp. 1136-1143 118 false true Reference 53613609 /api/reference/53613609 119. Ramos, E., O'Leary, M.E., State-dependent trapping of flecainide in the cardiac sodium channel (2004) J Physiol, 560, pp. 37-49 119 false true Reference 53613610 /api/reference/53613610 120. Hu, R.M., Tester, D.J., Li, R., Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients (2018) Channels, 12 (1), pp. 176-186 120 false true Reference 53613611 /api/reference/53613611 121. Terrenoire, C., Wang, K., Tung, K.W., Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics (2013) J Gen Physiol, 141 (1), pp. 61-72 121 false true Reference 53613612 /api/reference/53613612 122. Bankston, J.R., Yue, M., Chung, W., A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response (2007) PLoS One, 2 (12) 122 false true Reference 53613613 /api/reference/53613613 123. Mikuni, I., Torres, C.G., Bakshi, T., Enhanced effects of isoflurane on the long QT syndrome 1-associated A341V mutant (2015) Anesthesiology, 122 (4), pp. 806-820 123 false true Reference 53613614 /api/reference/53613614 124. Abdelsayed, M., Ruprai, M., Ruben, P.C., The efficacy of Ranolazine on E1784K is altered by temperature and calcium (2018) Sci Rep, 8 (1), p. 3643 124 false true Reference 53613615 /api/reference/53613615 125. Peters, C.H., Yu, A., Zhu, W., Silva, J.R., Ruben, P.C., Depolarization of the conductance-voltage relationship in the NaV1.5 mutant, E1784K, is due to altered fast inactivation (2017) PLoS One, 12 (9) 125 false true Reference 53613616 /api/reference/53613616 126. Sarhan, M.F., Tung, C.C., Van Petegem, F., Ahern, C.A., Crystallographic basis for calcium regulation of sodium channels (2012) Proc Natl Acad Sci U S A, 109 (9), pp. 3558-3563 126 false true Reference 53613617 /api/reference/53613617 127. Galleano, I., Harms, H., Choudhury, K., Khoo, K., Delemotte, L., Pless, S.A., Functional cross-talk between phosphorylation and disease-causing mutations in the cardiac sodium channel Na(v)1.5 (2021) Proc Natl Acad Sci U S A, 118 (33) 127 false true Reference 53613618 /api/reference/53613618 128. Tateyama, M., Kurokawa, J., Terrenoire, C., Rivolta, I., Kass, R.S., Stimulation of protein kinase C inhibits bursting in disease-linked mutant human cardiac sodium channels (2003) Circulation, 107 (25), pp. 3216-3222 128 false true Reference 53613619 /api/reference/53613619 129. Ruan, Y., Denegri, M., Liu, N., Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3 (2010) Circ Res, 106 (8), pp. 1374-1383 129 false true Reference 53613620 /api/reference/53613620 130. Zhang, J., Chen, Y., Yang, J., Electrophysiological and trafficking defects of the SCN5A T353I mutation in Brugada syndrome are rescued by alpha-allocryptopine (2015) Eur J Pharmacol, 746, pp. 333-343 130 false true Reference 53613621 /api/reference/53613621 131. Zou, X., Wu, X., Sampson, K.J., Colecraft, H.M., Larsson, H.P., Kass, R.S., Pharmacological rescue of specific long QT variants of KCNQ1/KCNE1 channels (2022) Front Physiol, 13 131 false true Reference 53613622 /api/reference/53613622 132. Seebohm, G., Pusch, M., Chen, J., Sanguinetti, M.C., Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels (2003) Circ Res, 93 (10), pp. 941-947 132 false true Reference 53613623 /api/reference/53613623 133. Salata, J.J., Jurkiewicz, N.K., Wang, J., Evans, B.E., Orme, H.T., Sanguinetti, M.C., A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents (1998) Mol Pharmacol, 54 (1), pp. 220-230 133 false true Reference 53613624 /api/reference/53613624 134. Mazzanti, A., Maragna, R., Vacanti, G., Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome (2018) J Am Coll Cardiol, 71 (15), pp. 1663-1671 134 false true /api/publication/34884013 Zhao Z. et al. Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome. (2024) EBIOMEDICINE 2352-3964 2352-3964 103<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Zhao Z. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Zang X.^* </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Niu K. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Song W. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Wang X. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Mügge A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Aweimer A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10086357"><a href="/gui2/?type=authors&mode=browse&sel=10086357" target="_blank">Hamdani N. (<span class="authorship-author-name">Hamdani Nazha</span> <span class="authorAux-mtmt"> Medicine</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM- SE Kardiovaszkuláris Komorbiditások Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Zhou X. ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Zhao Y. ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Akin I.^** </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >El-Battrawy I. </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34884013" target="_blank">Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome</a></div> <div> <span class="journal-title">EBIOMEDICINE</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2352-3964">2352-3964</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2352-3964">2352-3964</a>)</span>: <span class="journal-volume">103</span> <span class="page"> Paper 105108. 18 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.ebiom.2024.105108" target="_blank" href="https://doi.org/10.1016/j.ebiom.2024.105108"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001295888500001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001295888500001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85190829849" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85190829849"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38653189" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38653189&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 5</span> | Független: 3 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 5 | Scopus jelölt:&nbsp;3 | WoS/Scopus jelölt:&nbsp;5 | DOI jelölt:&nbsp;5 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34884013&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34884013</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2026.02.21. 18:13 Suchanek-Lukács Margit (Admin 3, admin) </div> </div></div>